Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury

Naoko Yokota, Michael O'Donnell, Frank Daniels, Melissa Burne-Taney, William Keane, Bertram Kasiske, Hamid Rabb

Research output: Contribution to journalArticle

Abstract

Background: Increasing evidence supports an important role for inflammation in the pathogenesis of renal ischemia-reperfusion injury (IRI). Recently, HMG-CoA reductase inhibitors, 'statins', have demonstrated anti-inflammatory effects independent of cholesterol-lowering. Hypothesis: We tested the hypothesis that a statin would improve outcome in a murine model of renal IRI. Upon finding a protective effect, we tested the hypothesis that the mechanisms by which statins protected in renal IRI was by reducing neutrophil and macrophage infiltration and upregulating the anti-inflammatory cytokine IL-6. Methods: Cerivastatin at various dosing regimens was administered to NIH Swiss mice to evaluate the effects on renal IRI. Analysis of renal structure, function, neutrophil and macrophage infiltration, cytokine production, as well as mortality was performed in cerivastatin- and saline-treated groups. Results: Primary: Cerivastatin pre-treatment for 3 days led to a significant improvement in renal function, tubular injury as well as survival after IRI compared to saline-treated mice. Secondary: Neutrophil and macrophage infiltration into kidney tissue was similar in both groups. IL-6 was markedly upregulated early in the kidneys of statin-treated compared to saline-treated mice. Conclusion: These data demonstrate that a statin compound can improve the course of ischemic acute renal failure. Induction of protective molecules such as IL-6 may underlie this effect.

Original languageEnglish (US)
Pages (from-to)13-17
Number of pages5
JournalAmerican Journal of Nephrology
Volume23
Issue number1
DOIs
StatePublished - 2003

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Reperfusion Injury
Kidney
Neutrophil Infiltration
Interleukin-6
Macrophages
Anti-Inflammatory Agents
Cytokines
Acute Kidney Injury
Cholesterol
Inflammation
Mortality
Wounds and Injuries

ASJC Scopus subject areas

  • Nephrology

Cite this

Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. / Yokota, Naoko; O'Donnell, Michael; Daniels, Frank; Burne-Taney, Melissa; Keane, William; Kasiske, Bertram; Rabb, Hamid.

In: American Journal of Nephrology, Vol. 23, No. 1, 2003, p. 13-17.

Research output: Contribution to journalArticle

Yokota, Naoko ; O'Donnell, Michael ; Daniels, Frank ; Burne-Taney, Melissa ; Keane, William ; Kasiske, Bertram ; Rabb, Hamid. / Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. In: American Journal of Nephrology. 2003 ; Vol. 23, No. 1. pp. 13-17.
@article{dd464b3044a7485b8f82110e3979d77e,
title = "Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury",
abstract = "Background: Increasing evidence supports an important role for inflammation in the pathogenesis of renal ischemia-reperfusion injury (IRI). Recently, HMG-CoA reductase inhibitors, 'statins', have demonstrated anti-inflammatory effects independent of cholesterol-lowering. Hypothesis: We tested the hypothesis that a statin would improve outcome in a murine model of renal IRI. Upon finding a protective effect, we tested the hypothesis that the mechanisms by which statins protected in renal IRI was by reducing neutrophil and macrophage infiltration and upregulating the anti-inflammatory cytokine IL-6. Methods: Cerivastatin at various dosing regimens was administered to NIH Swiss mice to evaluate the effects on renal IRI. Analysis of renal structure, function, neutrophil and macrophage infiltration, cytokine production, as well as mortality was performed in cerivastatin- and saline-treated groups. Results: Primary: Cerivastatin pre-treatment for 3 days led to a significant improvement in renal function, tubular injury as well as survival after IRI compared to saline-treated mice. Secondary: Neutrophil and macrophage infiltration into kidney tissue was similar in both groups. IL-6 was markedly upregulated early in the kidneys of statin-treated compared to saline-treated mice. Conclusion: These data demonstrate that a statin compound can improve the course of ischemic acute renal failure. Induction of protective molecules such as IL-6 may underlie this effect.",
author = "Naoko Yokota and Michael O'Donnell and Frank Daniels and Melissa Burne-Taney and William Keane and Bertram Kasiske and Hamid Rabb",
year = "2003",
doi = "10.1159/000066301",
language = "English (US)",
volume = "23",
pages = "13--17",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury

AU - Yokota, Naoko

AU - O'Donnell, Michael

AU - Daniels, Frank

AU - Burne-Taney, Melissa

AU - Keane, William

AU - Kasiske, Bertram

AU - Rabb, Hamid

PY - 2003

Y1 - 2003

N2 - Background: Increasing evidence supports an important role for inflammation in the pathogenesis of renal ischemia-reperfusion injury (IRI). Recently, HMG-CoA reductase inhibitors, 'statins', have demonstrated anti-inflammatory effects independent of cholesterol-lowering. Hypothesis: We tested the hypothesis that a statin would improve outcome in a murine model of renal IRI. Upon finding a protective effect, we tested the hypothesis that the mechanisms by which statins protected in renal IRI was by reducing neutrophil and macrophage infiltration and upregulating the anti-inflammatory cytokine IL-6. Methods: Cerivastatin at various dosing regimens was administered to NIH Swiss mice to evaluate the effects on renal IRI. Analysis of renal structure, function, neutrophil and macrophage infiltration, cytokine production, as well as mortality was performed in cerivastatin- and saline-treated groups. Results: Primary: Cerivastatin pre-treatment for 3 days led to a significant improvement in renal function, tubular injury as well as survival after IRI compared to saline-treated mice. Secondary: Neutrophil and macrophage infiltration into kidney tissue was similar in both groups. IL-6 was markedly upregulated early in the kidneys of statin-treated compared to saline-treated mice. Conclusion: These data demonstrate that a statin compound can improve the course of ischemic acute renal failure. Induction of protective molecules such as IL-6 may underlie this effect.

AB - Background: Increasing evidence supports an important role for inflammation in the pathogenesis of renal ischemia-reperfusion injury (IRI). Recently, HMG-CoA reductase inhibitors, 'statins', have demonstrated anti-inflammatory effects independent of cholesterol-lowering. Hypothesis: We tested the hypothesis that a statin would improve outcome in a murine model of renal IRI. Upon finding a protective effect, we tested the hypothesis that the mechanisms by which statins protected in renal IRI was by reducing neutrophil and macrophage infiltration and upregulating the anti-inflammatory cytokine IL-6. Methods: Cerivastatin at various dosing regimens was administered to NIH Swiss mice to evaluate the effects on renal IRI. Analysis of renal structure, function, neutrophil and macrophage infiltration, cytokine production, as well as mortality was performed in cerivastatin- and saline-treated groups. Results: Primary: Cerivastatin pre-treatment for 3 days led to a significant improvement in renal function, tubular injury as well as survival after IRI compared to saline-treated mice. Secondary: Neutrophil and macrophage infiltration into kidney tissue was similar in both groups. IL-6 was markedly upregulated early in the kidneys of statin-treated compared to saline-treated mice. Conclusion: These data demonstrate that a statin compound can improve the course of ischemic acute renal failure. Induction of protective molecules such as IL-6 may underlie this effect.

UR - http://www.scopus.com/inward/record.url?scp=0037210127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037210127&partnerID=8YFLogxK

U2 - 10.1159/000066301

DO - 10.1159/000066301

M3 - Article

C2 - 12373076

AN - SCOPUS:0037210127

VL - 23

SP - 13

EP - 17

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 1

ER -